For research use only. Not for therapeutic Use.
Tivumecirnon（Cat No.:I042310）is an investigational small molecule inhibitor designed to target and modulate the activity of Janus kinase 3 (JAK3), a key enzyme in the signaling pathway of cytokines that regulate immune cell function. By inhibiting JAK3, tivumecirnon aims to reduce inflammation and immune cell activation, making it a potential treatment for autoimmune diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease (IBD). Preclinical and early-phase clinical studies have shown promise in modulating immune responses while minimizing systemic side effects commonly seen with other JAK inhibitors.
| Catalog Number | I042310 |
| CAS Number | 2174938-78-2 |
| Synonyms | 2-[(3R)-3-[1-[1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-3-(trifluoromethyl)pyrazolo[3,4-b]pyrazin-6-yl]azetidin-3-yl]piperidin-1-yl]ethanol |
| Molecular Formula | C24H27Cl2F3N6O |
| Purity | ≥95% |
| IUPAC Name | 2-[(3R)-3-[1-[1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-3-(trifluoromethyl)pyrazolo[3,4-b]pyrazin-6-yl]azetidin-3-yl]piperidin-1-yl]ethanol |
| InChI | InChI=1S/C24H27Cl2F3N6O/c1-14(18-5-4-17(25)9-19(18)26)35-23-21(22(32-35)24(27,28)29)30-10-20(31-23)34-12-16(13-34)15-3-2-6-33(11-15)7-8-36/h4-5,9-10,14-16,36H,2-3,6-8,11-13H2,1H3/t14-,15+/m1/s1 |
| InChIKey | AKSVALRPYDVQBS-CABCVRRESA-N |
| SMILES | C[C@H](C1=C(C=C(C=C1)Cl)Cl)N2C3=NC(=CN=C3C(=N2)C(F)(F)F)N4CC(C4)[C@H]5CCCN(C5)CCO |
